On October 13, 2025, Nexalin Technology announced the addition of Dr. Robert Rothstein to its Scientific Advisory Board. Dr. Rothstein brings more than four decades of experience in emergency medicine, mental health interventions, and translational research, having held senior positions at the University of Chicago, Harbor/UCLA Medical Center, and Johns Hopkins Medicine.
The appointment strengthens Nexalin’s focus on Alzheimer’s disease and traumatic brain injury programs. Dr. Rothstein will support the company’s upcoming FDA Q‑submission for Alzheimer’s and TBI, helping shape clinical designs and regulatory strategy for its next‑generation neurostimulation devices.
The addition is significant for investors as it bolsters the company’s clinical expertise and regulatory roadmap, potentially accelerating product development and market entry for its Gen‑2 SYNC and Gen‑3 HALO devices.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.